Investor Tries To Stop LabCorp's $85M Orchid Buyout

Law360, New York (May 4, 2011, 2:07 PM EDT) -- Laboratory Corp. of America Holdings’ plan to buy DNA testing company Orchid Cellmark Inc. for $85 million spurred a shareholder class action in New Jersey on Monday claiming the expedited deal is grossly undervalued.

The disgruntled investor alleges the Orchid board fast-tracked the sale without trying to attain a competitive price for public shareholders, who would otherwise prosper as Orchid continues to expand in the United Kingdom and the U.S., according to the complaint.

While the proposed deal provides shareholders with a $2.80 buyout price, Orchid’s...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

TSATSIS v. ORCHID CELLMARK, INC. et al


Case Number

3:11-cv-02508

Court

New Jersey

Nature of Suit

Stockholders Suits

Judge

Anne E. Thompson

Date Filed

May 2, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.